Probiotics for Cardiovascular Protection

Using genetically-engineered microbes and their byproducts to lower cholesterol levels and reduce the risk of high cholesterol and associated diseases. The microbes are engineered to express enzymes called cholesterol oxidoreductases that metabolize cholesterol into coprostanol, a less absorbable form. The microbes can be delivered as probiotics or coprostanol and related compounds can be administered to reduce serum cholesterol levels.

Source

Using Faecalibacterium prausnitzii bacteria as a medicine to treat pathological ventricular remodeling and heart failure following a heart attack.

Source

Probiotic compositions containing specific strains of Lactobacillus bacteria (L. reuteri GMNL-89 and L. paracasei GMNL-133) for preventing stroke and mitigating the severity of stroke. The probiotics are taken as a dietary supplement to regulate intestinal microbiota, enhance intestinal barrier function, and reduce inflammatory responses to prevent ischemic stroke.

Source

Probiotic composition containing specific strains of bacteria that when combined reduce cholesterol and triglycerides in the blood. The composition includes Bifidobacterium lactis MN-Gup, Bifidobacterium lactis M8, Lactobacillus plantarum LP6, and Lactobacillus casei Zhang. The strains can be used to prevent, alleviate, or improve symptoms of high cholesterol and high triglycerides.

Source

A natural composition to support cardiovascular health by contributing to healthy serum cholesterol levels, reducing CRP and IL-6 cytokine levels, and promoting a healthy gut microbiome. The composition includes probiotic bacteria (Lactobacillus plantarum or Lactobacillus reuteri), cholesterol-lowering plant sterols, and Ashwagandha root powder.

Source

Using Bifidobacterium longum strain CCFM752 to prevent and treat cardiovascular diseases, especially hypertension. The strain has been found to significantly reduce blood pressure in hypertensive rats and decrease the levels of reactive oxygen species (ROS) that contribute to hypertension.

Source

A combination of Bacteroides vulgatus and Bacteroides dorei bacteria species, that can control LPS production by enteric bacteria and transfer thereof into the blood. This can reduce intestinal LPS levels, strengthen tight junctions in the intestinal barrier to reduce blood LPS levels, and suppress inflammatory responses and immune responses in intestines, blood vessels, and organs by co-existing in the intestines. It can provide a new way to prevent and improve circulatory diseases, inflammatory diseases, and metabolic diseases through ingestion of these bacteria.

Source

A combination of three probiotic strains, Bifidobacterium animalis WHH2276, Lactobacillus rhamnosus WHH1155, and Lactobacillus fermentum WHH3906, that synergistically lower blood lipids. The strains were selected based on their individual functions of reducing blood lipids, weight, and uric acid. Compared to single strains, the combination showed enhanced blood lipid-lowering effects. This synergy was confirmed through in vitro experiments. The combination is useful in preventing or treating hyperlipidemia-related diseases and symptoms.

Source

Use of Faecalibacterium prausnitzii, a bacteria commonly found in the intestines of mammals, in preparing a medicine for treating pathological ventricular remodeling and/or heart failure following myocardial infarction. The bacteria can improve cardiac function, reduce fibrosis, and inhibit hypertrophy after infarction.

Source

Functional food products for preventing non-communicable diseases like obesity, atherosclerosis, and type 2 diabetes by targeting intestinal microbiota correction. The products contain probiotic bacteria isolated from traditional dishes/drinks and natural prebiotics from fruits/vegetables. The bacteria strains, like Lactobacillus plantarum and Lactobacillus casei, are co-cultured with prebiotic compounds like apple pectin. This synergistic combination selectively inhibits pathogenic bacteria while promoting beneficial bacteria. The products aim to regulate intestinal microbiota for disease prevention through specific microbiota modulation.

Source

A multi-nutrient composition for treating and preventing oxidative stress conditions like cardiovascular disease. The composition includes vitamins, minerals, antioxidants, amino acids, probiotics, and other components.

Source

Composition containing lactic acid bacteria that can reduce heart rate when ingested. The lactic acid bacteria are generally from the Lactobacillus genus, and have specific activities like lowering IL-6 levels and boosting IL-10 production.

Source

Using a specific strain of Lactobacillus fermentum called LM1016 to prevent, ameliorate, and treat cardiovascular diseases, obesity, fatty liver, and diabetes mellitus without side effects. The LM1016 strain reduces levels of cardiovascular disease markers like CRP, neutral fat, and cholesterol, as well as body weight, fat accumulation, inflammation, blood sugar, insulin, and leptin levels. Administering LM1016 has potential as a natural alternative to drugs for managing these chronic conditions.

Source

A novel strain of Lactobacillus fermentum, LM1016, that can treat or prevent cardiovascular diseases, obesity, fatty liver and diabetes. The strain was found to reduce levels of C-reactive protein, cholesterol, neutral fat, blood sugar, and insulin while inhibiting weight gain and fatty liver development. Administering LM1016 can prevent or treat these chronic conditions.

Source

Using specific strains of lactic acid bacteria to treat obesity and obesity-related diseases like hypertension, fatty liver, and cardiovascular disease. The lactic acid bacteria strains, including Lactobacillus salivarius AP-32 and Bifidobacterium longum subsp. longum OLP-01, can inhibit fat absorption and reduce body fat. Administering these bacteria as a composition, such as in food or pharmaceuticals, provides a natural alternative to conventional obesity drugs with fewer side effects.

Source

Probiotic composition for hypertension treatment using Lactobacillus plantarum 2830 strain that effectively lower and control blood pressure, especially in people with mild hypercholesterolemia. The Lactobacillus plantarum 2830 strain can be used in medicaments or food supplements to prevent and treat hypertension.

Source

Using microbiome modulation to reduce LDL cholesterol in individuals with dyslipidemia or at risk of developing it. The method involves administering a microbiome treatment like prebiotics, probiotics, or antibiotics to alter gut bacteria levels. The efficacy is determined by monitoring Parasutterella bacterial levels in response, since increases correlate with LDL reduction.

Source

Probiotic composition and preparation method that have thrombolytic, lipid lowering, and intestinal flora regulating effects. The composition contains specific strains of lactobacilli that reduce cholesterol absorption and fat absorption in the gut. The method involves suppressing the rise of certain biological substances in lipid and cholesterol metabolism. This reduces cholesterol levels by inhibiting intestinal cholesterol absorption and hepatic fat absorption. The composition also lowers glutathione levels. The lactobacilli strains involved are Lactobacillus acidophilus and Lactobacillus casei.

Source

Lactobacillus reuteri CCFM1040 is used for improving the structure of intestinal flora, increasing the abundance of beneficial bacteria, and reducing the risk of constipation, enteritis, lactose intolerance, infection, inflammation, allergy, glycolipid metabolic disorder, obesity, nonalcoholic fatty liver, type II diabetes, and cardiovascular diseases. The microorganisms are controlled to reduce the level of plasma TMAO by 4.7 times compared with that of the model group, the abundance of the beneficial bacteria, namely the genus Bifidobacterium is improved by 4.7 times compared with that of the model group, the abundance of the beneficial bacteria, namely the genus Bifidobacterium is improved by 4.7 times compared with that of the model group, the abundance of the beneficial bacteria, namely the genus Bifidobacterium is improved by 4.7 times compared with that of the model group, and the risks of constipation, enteritis, lactose intolerance, infection, inflammation, allergy, glycolipid metabolic disorder, obesity, nonalcoholic fatty liver, type II diabetes and cardiovascular diseases are further reduced.

Source

The method of reducing the cholesterol content in food stuff by probiotic bacteria Bacillus coagulans, said method comprising step of bringing into contact the prebiotic bacteria, together with bile salts and bile acids, with foods rich in cholesterol, to bring about the reduction and assimilation of cholesterol from the food stuff by the probiotic bacteria. In a related embodiment, the Bacillus coagulans strain is Bacillus coagulans MTCC 5856. In another related embodiment, foods rich in cholesterol is selected from the group consisting of, but not limited to, chicken liver, egg yolk, fish and fish oils, fast foods, animal fats and oil, seafood, processed meat, red meat, cheese, milk fat, butter and confectioneries.

Source